Reflux Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 31-12-2024
- Paid Up Capital ₹ 7.68 M
as on 31-12-2024
- Company Age 4 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.50 Cr
as on 31-12-2024
- Satisfied Charges ₹ 5.18 Cr
as on 31-12-2024
- Revenue 386.06%
(FY 2022)
- Profit -5.71%
(FY 2022)
- Ebitda 16.11%
(FY 2022)
- Net Worth 91.01%
(FY 2022)
- Total Assets 63.69%
(FY 2022)
About Reflux Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 7.68 M.
The company currently has active open charges totaling ₹8.50 Cr. The company has closed loans amounting to ₹5.18 Cr, as per Ministry of Corporate Affairs (MCA) records.
Jaid Kojar, Sandeep Tekle, and Amit Ghosh serve as directors at the Company.
- CIN/LLPIN
U74999MH2020PTC337046
- Company No.
337046
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Feb 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- LocationThane, Maharashtra
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Reflux Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jaid Kojar  | Nominee Director | 29-Jul-2024 | Current |
| Sandeep Tekle | Director | 03-Feb-2020 | Current |
| Amit Ghosh | Director | 03-Feb-2020 | Current |
Financial Performance of Reflux Pharmaceuticals.
Reflux Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 386.06% increase. The company also saw a slight decrease in profitability, with a 5.71% decrease in profit. The company's net worth Soared by an impressive increase of 91.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Reflux Pharmaceuticals?
Unlock access to Reflux Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 09 Mar 2023 | ₹8.50 Cr | Open |
Others Creation Date: 17 Mar 2022 | ₹5.18 Cr | Satisfied |
How Many Employees Work at Reflux Pharmaceuticals?
Unlock and access historical data on people associated with Reflux Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Reflux Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Reflux Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
